Ann: SPP & shareholder update webinar, page-13

"Soon enough the tables will turn and Painchek will be the ones being approached, rather than employing reps to sell it." – and unless the company can solve the implementation bottleneck, those people who come flocking to Paincheck to sign orders are going to be dead (possibly in undiagnosed pain) and buried before the product is delivered to their grandchildren!

My point is that it doesn't matter how much demand there is for the product, if the company can't supply it, nobody is going to get any benefit from it: not the patients, not the carers, not the company, and certainly not we investors.